Abstract

MPT-0118 is an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease developed by Monopteros Therapeutics for the treatment of solid tumors. Despite the transforming effects of immune checkpoint therapy (ICT), objective response rates are still low in solid tumors. In the tumor microenvironment (TME), regulatory T-cells (Treg) are unstable and can be reprogrammed to lose their immunosuppressive function and secrete interferon-γ, offering a strategy to sensitize unresponsive tumors to ICT.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.